v3.25.1
Segment Reporting - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue    
Collaboration and license revenue $ 2,171 $ 566
Operating expenses:    
Research and development 29,788 24,857
General and administrative 8,633 7,082
Loss from operations (36,250) (31,373)
Other (expense) income:    
Interest and other income, net 2,802 2,190
Interest expense 679 959
Net loss (34,127) (30,142)
Reportable Segment    
Revenue    
Collaboration and license revenue 2,171 566
Operating expenses:    
Loss from operations (36,250) (31,373)
Other (expense) income:    
Interest and other income, net 2,802 2,190
Interest expense (679) (959)
Net loss (34,127) (30,142)
Reportable Segment | Laboratory Supplies, Research Materials and Studies    
Operating expenses:    
Research and development 9,489 7,276
Reportable Segment | Personnel Expenses    
Operating expenses:    
Research and development 8,816 7,707
General and administrative 3,019 2,668
Reportable Segment | Legal and Professional Fees    
Operating expenses:    
General and administrative 1,954 1,668
Reportable Segment | Facility-Related and Other    
Operating expenses:    
Research and development 5,548 3,901
General and administrative 1,808 1,647
Reportable Segment | Clinical Studies    
Operating expenses:    
Research and development 3,695 3,833
Reportable Segment | Stock-Based Compensation    
Operating expenses:    
Research and development 1,738 1,065
General and administrative 1,676 919
Reportable Segment | Depreciation Expense    
Operating expenses:    
Research and development 502 1,075
General and administrative $ 176 $ 180